Eli Lilly And Co (LLY) Stake Decreased by Cetera Investment Advisers

Cetera Investment Advisers cut its holdings in Eli Lilly And Co (NYSE:LLY) by 2.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,081 shares of the company’s stock after selling 153 shares during the quarter. Cetera Investment Advisers’ holdings in Eli Lilly And Co were worth $823,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in LLY. Captrust Financial Advisors grew its holdings in shares of Eli Lilly And Co by 0.4% during the fourth quarter. Captrust Financial Advisors now owns 21,627 shares of the company’s stock valued at $2,503,000 after buying an additional 87 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its holdings in shares of Eli Lilly And Co by 1.6% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 5,543 shares of the company’s stock worth $641,000 after purchasing an additional 87 shares during the period. First Personal Financial Services raised its holdings in shares of Eli Lilly And Co by 2.3% during the fourth quarter. First Personal Financial Services now owns 3,931 shares of the company’s stock worth $455,000 after purchasing an additional 89 shares during the period. Carroll Financial Associates Inc. grew its position in shares of Eli Lilly And Co by 1.3% during the fourth quarter. Carroll Financial Associates Inc. now owns 7,029 shares of the company’s stock worth $810,000 after acquiring an additional 91 shares during the last quarter. Finally, Bailard Inc. grew its position in shares of Eli Lilly And Co by 3.6% during the fourth quarter. Bailard Inc. now owns 2,672 shares of the company’s stock worth $309,000 after acquiring an additional 92 shares during the last quarter. 79.58% of the stock is currently owned by institutional investors and hedge funds.

LLY stock traded down $1.30 during mid-day trading on Friday, reaching $115.20. 9,805,773 shares of the stock traded hands, compared to its average volume of 6,415,027. The company has a current ratio of 1.73, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07. Eli Lilly And Co has a 52-week low of $77.09 and a 52-week high of $132.13. The firm has a market capitalization of $119.33 billion, a PE ratio of 20.76, a P/E/G ratio of 2.18 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The firm had revenue of $6.44 billion for the quarter, compared to analysts’ expectations of $6.28 billion. During the same period in the prior year, the company posted $1.14 earnings per share. Eli Lilly And Co’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, equities research analysts anticipate that Eli Lilly And Co will post 5.66 earnings per share for the current year.

LLY has been the subject of several recent research reports. UBS Group lowered their price target on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a research report on Friday, February 8th. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 price target for the company in a research report on Wednesday, April 10th. Bank of America set a $129.00 price target on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Thursday, March 21st. Barclays restated a “buy” rating and set a $130.00 price target on shares of Eli Lilly And Co in a research report on Sunday, January 20th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Eli Lilly And Co in a research report on Tuesday, March 12th. They set an “overweight” rating and a $140.00 price target for the company. Ten equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly And Co has an average rating of “Buy” and a consensus target price of $118.02.

In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $122.48, for a total value of $25,108,400.00. Following the completion of the sale, the insider now directly owns 117,641,684 shares of the company’s stock, valued at $14,408,753,456.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $128.50, for a total transaction of $128,500.00. The disclosure for this sale can be found here. Insiders have sold 867,382 shares of company stock valued at $109,265,182 over the last ninety days. Insiders own 0.11% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/eli-lilly-and-co-lly-shares-sold-by-cetera-investment-advisers.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Strangles

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.